Related Experiment Video
Updated: Jun 2, 2026
07:52
A Human Blood-Brain Interface Model to Study Barrier Crossings by Pathogens or Medicines and Their Interactions with the Brain
Published on: April 9, 2019
NAP (davunetide) provides functional and structural neuroprotection.
1The Adams Super Center for Brain Studies, Israel. igozes@post.tau.ac.i
Current Pharmaceutical Design
|April 29, 2011
Summary
Neuroprotective peptide NAP (davunetide) enhances memory and daily function by protecting microtubules and activating key cellular pathways. This peptide offers potential for treating cognitive deficits and neurodegenerative diseases.
Area of Science:
- Neuroscience
- Molecular Biology
- Pharmacology
Background:
- Activity-dependent neuroprotective protein (ADNP) is crucial for brain development and cognitive function.
- Partial loss of ADNP leads to cognitive deficits and tauopathy.
- NAP (davunetide) is a neuroprotective peptide derived from ADNP.
Purpose of the Study:
- To elucidate the neuroprotective mechanisms of NAP (davunetide).
- To investigate NAP's role in protecting microtubules and neuronal survival.
- To explore NAP's therapeutic potential in cognitive impairment and neurodegenerative diseases.
Main Methods:
- In vitro and in vivo studies.
- Clinical trials in patients with mild cognitive impairment and schizophrenia.
- Analysis of microtubule stability, tau protein interactions, and cellular signaling pathways (PI-3K/Akt, MAPK/MEK1).
Main Results:
- NAP demonstrated potent neuroprotection in vitro and in vivo.
- Clinical trials showed NAP improved memory in mild cognitive impairment and daily behaviors in schizophrenia.
- NAP protects microtubules from katanin disruption and reduces apoptotic neurons via PI-3K/Akt and MAPK/MEK1 pathways.
Conclusions:
- NAP (davunetide) exhibits significant neuroprotective properties with therapeutic potential.
- NAP's mechanisms involve microtubule stabilization and activation of key survival signaling pathways.
- Further research into NAP's interaction with these pathways may advance clinical neuroprotection strategies.
Related Concept Videos
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function. They...
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
01:22Botulism
Botulism is a life-threatening neuroparalytic condition caused by botulinum neurotoxin, which is produced by the bacterium Clostridium botulinum, a Gram-positive, spore-forming, obligate anaerobe.In adults, the toxin enters the body in different ways: in foodborne botulism, the preformed toxin is absorbed in the intestine. In wound botulism, spores grow in injured tissue and release the toxin into the blood. Infant botulism differs mechanistically from adult forms. In infants, botulism commonly...
01:29Drug Delivery: Parenteral Route
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
01:29Drugs Affecting Neurotransmitter Synthesis
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...